X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced its upcoming earnings call on November 4, 2021, at 9:05 a.m. ET. The call will cover the third quarter financial results and recent business highlights. Additionally, the company is expected to discuss abstracts accepted for the 63rd American Society of Hematology (ASH) Annual Meeting, with publication set for the same day at 9:00 a.m. ET. X4 is focused on developing mavorixafor, a novel CXCR4-targeted therapy, currently undergoing clinical trials for various rare diseases.

Earnings Call taking place at 9:05 a.m. ET expected to include discussion of abstracts accepted to the upcoming 63rd American Society of Hematology (ASH) Annual Meeting

BOSTON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the third quarter ended September 30, 2021, and provide an update on recent business highlights, on November 4, 2021.

The company will host a conference call and webcast on the same day at 9:05 a.m. ET to discuss these financial results and business highlights. The company also anticipates discussion of abstracts accepted to the upcoming 63^rd American Society of Hematology (ASH) Annual Meeting and expected to be published at 9:00 a.m. ET on November 4^th.

The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 7582968. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases of the immune system via antagonism of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a number of clinical trials, including a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia (SCN) and other chronic neutropenia disorders. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, to discover and develop additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com

FAQ

What are the earnings results for XFOR for Q3 2021?

X4 Pharmaceuticals will report its earnings results for the third quarter ended September 30, 2021, on November 4, 2021.

When is the X4 Pharmaceuticals earnings call?

The earnings call for X4 Pharmaceuticals is scheduled for November 4, 2021, at 9:05 a.m. ET.

What topics will be discussed in the XFOR earnings call?

The XFOR earnings call will include discussions on financial results, recent business highlights, and abstracts accepted for the ASH Annual Meeting.

What is the significance of the ASH Annual Meeting for X4 Pharmaceuticals?

The ASH Annual Meeting is significant for X4 Pharmaceuticals as it provides a platform for discussing their research and findings related to their drug mavorixafor.